The EXERT trial didn't test rope flow. It tested hard aerobic exercise against gentle stretching in early memory decline — and the tie is the lesson.
If you read my piece on the SPARX trial, you know the lesson from Parkinson's research: intensity mattered. The hard group held their ground. The moderate group didn't separate from doing nothing.
So what happens when you run the same kind of test in early memory decline — and the gentle group holds, too?
That's the EXERT trial (Baker et al., Alzheimer's & Dementia, 2025). It was a phase 3 trial — the big, definitive kind — and if you or someone you love is watching memory slip and wondering whether exercise actually does anything, it's worth understanding exactly what it found, and what it didn't.
What the trial actually did
EXERT enrolled 296 sedentary adults with amnestic mild cognitive impairment — MCI. That's early, measurable memory decline, the stage that often comes before an Alzheimer's diagnosis. Not Alzheimer's itself. The window before it.
Participants were randomized to one of two programs:
- Moderate-high intensity aerobic training — heart rate at roughly 70–85% of heart rate reserve
- Low-intensity stretching, balance, and range of motion — heart rate kept below 35% of heart rate reserve
Both groups trained four times a week, supervised by a trainer at a YMCA for the first 12 months, then continued on their own for six more. Cognition was measured with a global cognitive composite (ADAS-Cog-Exec), and adherence was high — 81% of supervised sessions in the aerobic group, 87% in the stretching group. Over 31,000 sessions in the first year alone.
This was not a casual test. It was designed to answer a sharp question: for a brain already in early decline, does hard aerobic exercise beat gentle movement?
The result: a tie — and nobody declined
The aerobic group did not beat the stretching group. The difference between them on cognition at 12 months wasn't significant (p = 0.3).
But here's the finding inside the tie: neither group declined.
In MCI, decline is the expected trajectory. It's why the trial was run — the researchers expected to measure how much less the exercisers slipped. Instead, over 12 months, cognition in both groups stayed stable, and hippocampal volume loss — the brain region memory depends on, shrinking — was low in both, at 0.51%.
A gentle stretching and balance program held the line just as well as hard aerobic training.
The detail most people miss
Here's the part that doesn't make the headlines, and it's a two-parter.
First: EXERT had no no-exercise group inside the trial. Both arms exercised. So where does the "exercise beat usual care" claim come from? A separate, preplanned companion analysis compared both EXERT groups against a propensity-matched usual-care cohort drawn from the ADNI-1 study (Shadyab et al., 2025). In that comparison, both exercise groups showed significantly less 12-month cognitive decline than the matched usual-care group.
That's real — and it's weaker than a randomized control. A matched external cohort is not the same as people randomized to sit out. The authors' own language is careful for a reason: exercise may provide protection against decline relative to usual care, and the finding warrants further study.
Second: the "gentle" group wasn't doing nothing. Stretching, balance, and range of motion, four times a week, supervised, on a schedule, with a trainer and other people in the room. Balance asks the brain to work. Structure asks you to show up. Whatever the active ingredient was, "sitting at home" doesn't contain it.
What it doesn't prove
Let me be straight with you, because this is where most fitness content goes off the rails:
- This was MCI — early memory decline — not diagnosed Alzheimer's disease. Don't let anyone round that up.
- The headline comparison inside the trial was a tie. Intensity did not separate the groups on cognition. Anyone quoting EXERT as proof that hard cardio protects memory is quoting it wrong — and anyone quoting it as proof exercise does nothing is skipping the part where nobody declined.
- The usual-care comparison came from a matched external cohort, not a randomized arm. Suggestive, not definitive.
- It did not test rope flow. There are currently zero clinical trials on rope flow for Alzheimer's, MCI, or dementia. Zero. Anyone who tells you otherwise is selling something.
- Nobody — not the researchers, not me — is saying exercise cures Alzheimer's.
What the trial supports is narrower and still powerful: in early memory decline, people who trained consistently for a year — hard or gentle — held their cognition stable instead of following the expected slide, and they declined less than a matched group getting usual care. That's it. That's the claim. And it's enough to take seriously.
Why I train the way I do
Here's where I connect the dots — and I'll label this clearly as my coaching thesis, not a studied fact.
I'll be honest about the tension: SPARX said intensity was the difference. EXERT says intensity wasn't. Different disease, different outcome, different comparison — Parkinson's motor symptoms against a usual-care arm is not MCI cognition against an active control. I don't get to pick only the trial that flatters intensity, and neither do you.
So what survives across all three pieces of evidence I've written about? SPARX: the group that trained hard held. Tang's 67-trial analysis: the winners were the exercises that stimulate neural regulation. EXERT: both groups that showed up four times a week, for a year, with structure and balance and coordination in the mix, held.
The common thread isn't a heart-rate zone. It's consistent, structured movement that involves the brain — started early, while there's still ground to hold.
That's the mistake I see: training your body like the brain wasn't in the room. Sets and reps on autopilot while the system that's actually in decline gets nothing to solve. My work starts from the other end: rhythm your brain can lock onto, cross-body patterns that force both hemispheres to communicate, balance it has to earn, novel sequences it has to learn — because learning and sequencing are exactly what early decline goes after.
That's not a studied outcome. That's a coach connecting the trials to motor neuroscience and testing it in the real world, every day, with real people.
The takeaway
By the time a diagnosis arrives, the decline has usually been running for years. EXERT is a study of the window before that — and in that window, the people who moved, consistently and with structure, held their ground.
Don't wait for the label to start. Don't assume it has to be brutal to count, and don't assume a gentle program is the same as doing nothing — this trial says it isn't. Talk to your clinician about what fits your situation, and start while holding your ground is still the available outcome.
And if you want a place to start — the same neurological inputs I described above, in short daily sessions — my free Neuro-Reset Protocol is where I put them: skool.com/becoming-undeniable-4193
Educational content, not medical advice. Talk to your clinician or a movement specialist before starting an exercise program.
References: Baker L.D. et al. (2025). Effects of exercise on cognition and Alzheimer's biomarkers in a randomized controlled trial of adults with mild cognitive impairment: The EXERT study. Alzheimer's & Dementia, 21(4), e14586. DOI: 10.1002/alz.14586. / Shadyab A.H. et al. (2025). Effects of exercise versus usual care on older adults with amnestic mild cognitive impairment: EXERT versus ADNI. Alzheimer's & Dementia, 21(4), e70118. DOI: 10.1002/alz.70118.
